ARDX

2.9902.29%
RB

Robert B. Bazemore

Independent Director

Mr. Robert B. Bazemore, Jr. also known as Rob, is Director of Eupraxia Pharmaceuticals Inc. from June 18, 2026. Mr. Bazemore serves as Independent Director of Akari Therapeutics, Plc since September 17, 2024. He served as Vice President of Capital Planning Carolinas & Florida at Progress Energy Inc. Mr. Bazemore served as Vice President of Capital Planning at Florida Power Corp. He has over 22 years of biopharmaceutical experience, with 12 years at Johnson & Johnson in various roles including Vice President, Ethicon New Growth Platforms. He served as Vice President of Global Surgery at Ethicon from October 2013 to September 2014. He also served as Vice President, Marketing and Sales of Centocor Ortho Biotech, Inc., from 2008 to 2010 and Worldwide Vice President, Global Strategic Marketing. He served as Vice President of Capital Planning & Control of Progress Energy Inc. since June 1, 2005. He served as Chief Accounting Officer of Progress Energy Inc. since June 2000 and also served as its Vice President of Capital Planning & Control and Vice President of Regulated Fuels. He served as Chief Accounting Officer of Florida Progress Corporation since November 30, 2000. He served as Chief Accounting Officer and Controller of Duke Energy Progress, Inc. from May 2000 to May 2006 and as Chief Accounting Officer of North Carolina Natural Gas Corporation since December 2000. He began his career at Johnson & Johnson in 2002 and held numerous senior commercial positions having led the worldwide immunology portfolio strategy and the launches of multiple new products and indications. He was Vice President of Centocor Ortho Biotech Sales & Marketing from 2008 to 2010 and President of Janssen Biotech. He worked at Merck & Co., Inc. for eleven years in roles of increasing responsibility in Medical Affairs, Sales and Marketing, including Worldwide Marketing, Respiratory Franchise Business Group and was a Member of the marketing team that launched Singulair(R) (montelukast) in the U.S. Mr. Bazemore served as Vice President and Controller of Florida Progress Corporation since November 30, 2000. From 2015 to 2021, Mr. Bazemore served as the President, Chief Executive Officer and member of the Board of Directors of Epizyme Inc., developing and launching TAZVERIK for patients with Follicular Lymphoma and Sarcoma while building on the company???s pipeline of promising epigenetic candidates in oncology. Prior to that, from September 2014 to June 2015, Mr. Bazemore served as the Chief Operating Officer of Synageva BioPharma Corp. Mr. Bazemore served as Vice President of Accounting with Progress Energy Inc., since 2000 and Controller since June 2000. He served as Controller of Duke Energy Florida, Inc. (alternate name Florida Power Corporation) since November 30, 2000 and its Chief Accounting Officer. He served as Vice President of Progress Energy Service Company LLC and Controller of Progress Energy Service Company LLC, the Subsidiaries of Progress Energy Inc. since 2000. Prior to joining Progress Energy, Mr. Bazemore worked in Managerial and accounting positions with companies in Roanoke, VA and Jacksonville, FL. Mr. Bazemore served on the board of Neon Therapeutics prior to its acquisition by BioNTech and served as Board Chairman for Pennsylvania BIO. Mr. Bazemore serves on the Board of Directors of Ardelyx Inc. since June 2016 and as the Lead Independent Director of Nuvation Bio Inc. since July 2020.He served as Controller of North Carolina Natural Gas Corporation from November 2000 to December 2001 and a Director of Carolina Power & Light Company, Operations & Environmental Support Department from December 1998 to May 2000 and Manager of Carolina Power & Light Company, Financial & Regulatory Accounting from September 1995 to December 1998. He served as Outside Director of AgCarolina Farm Credit, ACA (alternate name AgCarolina Financial, ACA). He obtained a Bachelor of Science in Biochemistry from the University of Georgia.

Positions